Skip to main content

Table 2 Demographic data and characteristics of the subjects in total, including those in the incidence study, and those who completed the incidence studya, b

From: Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study

  Total participants (N = 57) Subjects included the study (N = 44) Subjects completed the study (N = 35)
Number of male patients 24 (42.1) 18 (40.9) 13 (37.1)
Age, years 37.5 ± 12.7 35.5 ± 11.9 34.7 ± 11.2
Age at schizophrenia onset, years 28.5 ± 11.9 26.8 ± 11.1 26.0 ± 10.3
Duration of antipsychotic treatment 8.4 ± 6.3 8.2 ± 6.5 8.1 ± 6.3
Number of hospitalizations 1.8 ± 2.2 1.8 ± 2.5 1.6 ± 2.3
Patients taking second-generation antipsychoticsc (including, clozapine, olanzapine, risperidone, and sertindole) 33 (57.9) 24 (54.5) 19 (54.3)
Patients reporting metabolic disturbances in their 1st degree relatives    
   1. Obesity 6 (10.5) 5 (11.4) 3 (8.6)
   2. Dyslipidemia 5 (8.8) 4 (9.1) 3 (8.6)
   3. Hypertension 20 (35.1) 15 (34.1) 13 (37.1)
   4. Diabetes mellitus 8 (14.0) 6 (13.6) 4 (11.4)
Patients with cluster diseases of MetS    
   1. Obesity (BMI ≥ 30 kg/m2) 4 (7.0) 2 (4.5) 2 (5.7)
   2. Central obesity (waist circumference ≥ 90 cm for men or ≥ 80 cm for women) 27 (47.4) 14 (31.8) 11 (31.4)
   3. High triglyceride level (≥ 150 mg/dL) 22 (38.6) 12 (27.3) 10 (28.6)
   4. Low HDL cholesterol level (<40 mg/dL for men or <50 mg/dL for women) 16 (28.1) 10 (22.7) 8 (22.9)
   5. High blood pressure (≥ 130/≥ 85 mm Hg) 17 (29.8) 11 (25.0) 8 (22.9)
   6. High fasting glucose level (≥ 100 mg/dL) 16 (28.1) 8 (18.2) 6 (17.1)
  1. aData shown as mean ± SD and N (%)
  2. bNo significant difference (p > 0.05) for all comparisons.
  3. cThe rest were taking first-generation antipsychotics.
  4. Abbreviation: BMI = body mass index, HDL = high-density lipoprotein.